Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.
Among 265 methicillin-susceptible and -resistant staphylococci, CB-181963 (CAB-175) had a 50% minimum inhibitory concentration of 2 microg/ml and a 90% minimum inhibitory concentration of 4 microg/ml. All strains except two vancomycin-resistant S. aureus and 5 vancomycin-intermediate S. aureus strains were also susceptible to vancomycin and teicoplanin, and all were susceptible to linezolid, ranbezolid, tigecycline, and quinupristin-dalfopristin. Most methicillin-resistant strains were levofloxacin resistant. CB-181963 was bactericidal against all six methicillin-resistant strains at four times the MIC after 24 h.
Hoellman
Dianne B
DB
Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, USA.
Pankuch
Glenn A
GA
Appelbaum
Peter C
PC
D000900:Anti-Bacterial Agents; D002511:Cephalosporins / Q000008:administration & dosage / Q000494:pharmacology*; D015169:Colony Count, Microbial; D007700:Kinetics; D016106:Methicillin Resistance; D013211:Staphylococcus aureus / Q000187:drug effects*; D020713:Vancomycin Resistance
D000900:Anti-Bacterial Agents; C489158:CB 181963; D002511:Cephalosporins